Drug news
Shire PLC ends development of SHP 656 a proposed treatment for hemophilia A.
Xenetic Biosciences Inc.announced that its partner Shire PLC has ended development of SHP 656 for hemophilia A, because the long-acting coagulation Factor VIII could not be dosed once-weekly, according to results from a Phase I/II trial. The effect has deprived the product of its chance of differentiation in the crowded hemophilia A marketplace.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.